The previous overviews provided the basis for better therapeutic efficacy/t
olerability of low to moderate affinity NMDA channel blockers. This predict
ion finds support in in vitro studies comparing protective and plasticity i
mpairing effects (therapeutic vs. side-effect) of memantine and (+)MK-801.
In fact it turned out that memantine had a far better therapeutic index. Bu
t can it be confirmed in the in vivo situation?